Catavax
Catavax uses AI to predict and treat cancers expressing MHC-II using a newly discovered immune mechanism. The approach relies on an AI model trained to predict MHC binding of peptides to guide therapy. Catavax operates as a biotech company delivering AI-driven cancer therapies. Its platform targets cancers such as breast, prostate, skin, lung, and colorectal cancers and seeks scalable partnerships with clinicians and researchers.
Catavax
Catavax uses AI to predict and treat cancers expressing MHC-II using a newly discovered immune mechanism. The approach relies on an AI model trained to predict MHC binding of peptides to guide therapy. Catavax operates as a biotech company delivering AI-driven cancer therapies. Its platform targets cancers such as breast, prostate, skin, lung, and colorectal cancers and seeks scalable partnerships with clinicians and researchers.